Tamoxifen
When ATH:
L02BA01
Characteristic.
The antitumor agent (antiestrogen).
Pharmacological action.
Antitumor, antiestrogens.
Application.
Mammary cancer, especially in women in menopause, endometrial cancer, kidney, soft tissue sarcoma, anovulatory infertility, oligospermatism, pituitary tumor.
Contraindications.
Hypersensitivity, pregnancy, tromboflebit.
Restrictions apply.
Leukopenia, thrombocytopenia, hypercalcemia.
Pregnancy and breast-feeding.
Category actions result in FDA - D. (There is evidence of the risk of adverse effects of drugs on the human fetus, obtained in research or practice, However, the potential benefits, associated with drugs in pregnant, may justify its use, in spite of the possible risk, if the drug is needed in life-threatening situations or severe disease, when safer agents should not be used or are ineffective.)
Side effects.
Gastrointestinal disorders (anorexia, nausea, vomiting), dizziness, skin rash, hypercalcemia, thrombocytopenia, moderate metrorrhagia, thrombosis, very rarely is the increase in body temperature, only rarely is a clouding of the cornea, degeneration setchatki.
Cooperation.
Cytostatics increase the risk of thrombosis. It can be successfully used in combination with progestins.
Dosing and Administration.
Inside, breast cancer, endometrial, kidneys — on 10-20 mg 2-3 times a day, the rate is 2.4-9.6 g; treatment is carried out before signs of regression process and in the next 1-2 months. When anovulatornom barrenness appoint 10 mg 2 twice a day for 4 days, starting from 2 day of menstruation, further dose can be increased up to 20 mg, and then — 40 mg. In the event of termination of Office of milk after childbirth — on 10 mg 4 twice a day for 5 days. When oligospermia is on 10 mg 2 once a day.
Precautions.
In the course of treatment is necessary to control the number of leukocytes, Platelet, calcium levels, indicators of blood coagulation.
Cautions.
Not only is effective in the treatment of patients with metastatic (especially in the liver).
Cooperation
| Active substance | Description of interaction |
| Bleomycin | FMR: synergism. Increases (mutually) the risk of venous thromboembolism. |
| Bromocriptine | FKV. Increases plasma levels. |
| Busulfan | FMR: synergism. Strengthens (mutually) toxicity. |
| Warfarin | FMR: synergism. Against the background of the effect of tamoxifen is enhanced. |
| Vynkrystyn | FMR: synergism. Increases (mutually) the risk of thromboembolic complications. |
| Dakarʙazin | FMR. Against the background of tamoxifen increases the risk of liver damage. |
| Daunorubicin | FMR: synergism. Increases (mutually) the risk of venous thromboembolism. |
| Doxorubicin | FMR: synergism. Increases (mutually) the likelihood of side effects. |
| Levothyroxine sodium | FKV. Against the background of changes tamoxifen binding to plasma proteins; the combined appointment of caution. |
| Methotrexate | FMR: synergism. Against the background of tamoxifen increases the risk of thromboembolic complications. |
| Mytoksantron | FMR: synergism. Against the background of tamoxifen increases the likelihood of thromboembolic complications. |
| Procarbazine | FMR: synergism. Against the background of tamoxifen increases the likelihood of thromboembolic complications. |
| Phenobarbital | FKV. It accelerates biotransformation and may cause a decrease in plasma concentrations. |
| Cyclophosphamide | FMR: synergism. Against the background of tamoxifen increases the likelihood of thromboembolic complications. |
| Epirubicin | FMR: synergism. Increases (mutually) the risk of toxic effects, especially from the blood and digestive tract. |
